Achaogen Company Profile (NASDAQ:AKAO)

About Achaogen

Achaogen logoAchaogen, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterials to treat multi-drug resistant (MDR) gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant enterobacteriaceae (CRE). Plazomicin is an aminoglycoside designed to overcome clinically relevant aminoglycoside resistance mechanisms. In addition, its research and development pipeline includes two programs that specifically target Pseudomonas aeruginosa or Acinetobacter baumannii infections: a program to discover and develop small molecule inhibitors of LpxC, which is an enzyme essential for the synthesis of the outer membrane of gram-negative bacteria, and a therapeutic antibody program. Its development plan for plazomicin includes over two Phase III clinical trials.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AKAO
  • CUSIP:
Key Metrics:
  • Previous Close: $23.65
  • 50 Day Moving Average: $18.38
  • 200 Day Moving Average: $9.02
  • 52-Week Range: $2.59 - $24.18
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -10.90
  • P/E Growth: 0.00
  • Market Cap: $649.22M
  • Outstanding Shares: 27,451,000
  • Beta: 1.35
Profitability:
  • Net Margins: -147.80%
  • Return on Equity: -143.44%
  • Return on Assets: -71.22%
Debt:
  • Debt-to-Equity Ratio: 0.77%
  • Current Ratio: 4.00%
  • Quick Ratio: 4.00%
Additional Links:
Companies Related to Achaogen:

Analyst Ratings

Consensus Ratings for Achaogen (NASDAQ:AKAO) (?)
Ratings Breakdown: 8 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $22.71 (3.96% downside)

Analysts' Ratings History for Achaogen (NASDAQ:AKAO)
Show:
DateFirmActionRatingPrice TargetDetails
2/23/2017AegisBoost Price Target$29.00View Rating Details
2/7/2017Stifel NicolausInitiated CoverageBuy$27.00View Rating Details
1/31/2017WedbushInitiated CoverageOutperform$19.00 -> $23.00View Rating Details
1/24/2017GuggenheimReiterated RatingBuy$30.00View Rating Details
1/4/2017Leerink SwannInitiated CoverageOutperform$21.00View Rating Details
12/13/2016Cowen and CompanyReiterated RatingBuyView Rating Details
12/12/2016Needham & Company LLCUpgradeHold -> Buy$19.00View Rating Details
9/26/2016SunTrust Banks, Inc.Reiterated RatingBuy$10.00View Rating Details
8/10/2015Cantor FitzgeraldReiterated RatingBuy$13.00View Rating Details
3/2/2015Credit Suisse GroupDowngradeOutperform -> Underperform$22.00 -> $13.00View Rating Details
(Data available from 2/24/2015 forward)

Earnings

Earnings History for Achaogen (NASDAQ:AKAO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2017        
11/7/2016Q3($0.61)($0.41)$8.72 million$16.05 millionViewListenView Earnings Details
8/8/2016Q2($0.67)($0.87)$5.58 million$9.14 millionViewN/AView Earnings Details
3/15/2016Q414($0.58)($0.61)$5.33 million$4.70 millionViewListenView Earnings Details
11/5/2015($0.45)($0.48)ViewN/AView Earnings Details
8/10/2015($0.20)($0.05)ViewN/AView Earnings Details
5/11/2015($0.26)($0.34)ViewN/AView Earnings Details
3/16/2015($0.33)($0.27)ViewN/AView Earnings Details
11/10/2014Q314($0.25)($0.47)$6.00 million$4.52 millionViewN/AView Earnings Details
8/11/2014($0.19)($0.20)ViewN/AView Earnings Details
5/12/2014Q114($0.48)($1.00)$5.39 million$6.00 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Achaogen (NASDAQ:AKAO)
Current Year EPS Consensus Estimate: $-2.33 EPS
Next Year EPS Consensus Estimate: $-2.17 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($0.71)($0.52)($0.62)
Q2 20164($0.71)($0.52)($0.62)
Q3 20163($0.53)($0.33)($0.43)
Q4 20164($0.76)($0.34)($0.51)
Q1 20172($0.59)($0.48)($0.54)
Q2 20172($0.64)($0.58)($0.61)
Q3 20172($0.75)($0.68)($0.72)
Q4 20172($0.71)($0.50)($0.61)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Achaogen (NASDAQ:AKAO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Achaogen (NASDAQ:AKAO)
Insider Ownership Percentage: 13.80%
Institutional Ownership Percentage: 44.47%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/26/2017Gary LoebGeneral CounselSell521$16.78$8,742.38View SEC Filing  
1/26/2017Ian FriedlandInsiderSell695$16.78$11,662.10View SEC Filing  
1/26/2017Kenneth J. HillanCEOSell1,431$16.78$24,012.18View SEC Filing  
1/26/2017Tobin SchilkeCFOSell955$16.78$16,024.90View SEC Filing  
1/26/2017Zeryn SarpangalVPSell781$16.78$13,105.18View SEC Filing  
12/19/2016Equity Opportunities Iv GrowthMajor ShareholderBuy500,000$13.50$6,750,000.00View SEC Filing  
9/27/2016Blake WiseCOOSell3,632$4.30$15,617.60View SEC Filing  
9/27/2016Zeryn SarpangalVPSell1,069$4.30$4,596.70View SEC Filing  
3/17/2016Ian FriedlandInsiderSell1,772$3.22$5,705.84View SEC Filing  
3/17/2016Kenneth J HillanCEOSell3,572$3.22$11,501.84View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Achaogen (NASDAQ:AKAO)
DateHeadline
4-traders.com logoAchaogen : Announces Achievement of a Key Milestone in Developing a Plazomicin Assay to Support Therapeutic Drug Management (TDM) (NASDAQ:AKAO)
www.4-traders.com - February 24 at 3:29 PM
marketexclusive.com logoAnalyst Activity – Aegis Raises Its Price Target On Achaogen (NASDAQ:AKAO) to (NASDAQ:AKAO)
marketexclusive.com - February 24 at 3:29 PM
News IconFiscal Year Earnings Estimate on Achaogen, Inc.(AKAO) (NASDAQ:AKAO)
mundoaguaysaneamiento.net - February 24 at 3:29 PM
us.rd.yahoo.com logoAchaogen Announces Leadership Promotions (NASDAQ:AKAO)
us.rd.yahoo.com - February 24 at 3:29 PM
us.rd.yahoo.com logo4:02 pm Achaogen promotes Blake Wise to President and Chief Operating Officer (NASDAQ:AKAO)
us.rd.yahoo.com - February 24 at 3:29 PM
News IconAnalyst Advice And Earnings Insight: Achaogen, Inc. (AKAO), Cerulean Pharma Inc. (CERU) - Post Analyst (NASDAQ:AKAO)
www.postanalyst.com - February 24 at 3:29 PM
News IconStock Survey: Viewing Levels for Achaogen, Inc. (NASDAQ:AKAO) - Midway Monitor (NASDAQ:AKAO)
midwaymonitor.com - February 24 at 3:29 PM
News IconAnalysts Peer Into Their Crystal Balls For Achaogen, Inc. (NASDAQ:AKAO): Where Is It headed? - Winfield Review (NASDAQ:AKAO)
winfieldreview.com - February 24 at 11:00 AM
News IconAre Institutions Putting Their Stamp of Approval On Achaogen, Inc ... - Rockville Register (NASDAQ:AKAO)
rockvilleregister.com - February 23 at 8:28 PM
streetinsider.com logoAchaogen (AKAO) Names Blake Wise President and COO - StreetInsider.com (NASDAQ:AKAO)
www.streetinsider.com - February 23 at 8:28 PM
News IconMixed Volatile Day (NASDAQ:AKAO)
www.fxstreet.com - February 23 at 1:29 AM
streetinsider.com logoAchaogen (AKAO) Reports Milestone in Developing Plazomicin Assay (NASDAQ:AKAO)
www.streetinsider.com - February 23 at 1:29 AM
News IconInvestor Watch on Shares of Achaogen, Inc. (NASDAQ:AKAO) - Baldwin Journal (NASDAQ:AKAO)
baldwinjournal.com - February 22 at 8:29 PM
News IconEarnings Take Center Stage; Analysts Weighing in on Achaogen, Inc. (NASDAQ:AKAO) - Aiken Advocate (NASDAQ:AKAO)
aikenadvocate.com - February 22 at 8:29 PM
streetinsider.com logoAchaogen (AKAO) Reports Milestone in Developing Plazomicin Assay - StreetInsider.com (NASDAQ:AKAO)
www.streetinsider.com - February 22 at 8:29 PM
finance.yahoo.com logo4:01 pm Achaogen achieves a strategic milestone in their ongoing efforts to develop an assay enabling therapeutic drug management (:TDM) of plazomicin (NASDAQ:AKAO)
finance.yahoo.com - February 22 at 8:29 PM
finance.yahoo.com logoAchaogen Announces Achievement of a Key Milestone in Developing a Plazomicin Assay to Support Therapeutic Drug Management (TDM) (NASDAQ:AKAO)
finance.yahoo.com - February 22 at 8:29 PM
News IconShares to Watch: Indicator Update on Achaogen Inc (AKAO) - Sherwood Daily (NASDAQ:AKAO)
sherwooddaily.com - February 22 at 11:37 AM
News IconAchaogen, Inc. (NASDAQ:AKAO) Touches into Overbought RSI Levels - Aiken Advocate (NASDAQ:AKAO)
aikenadvocate.com - February 21 at 3:42 PM
News IconLooking at the Numbers for Achaogen, Inc. (NASDAQ:AKAO) - BVN (NASDAQ:AKAO)
bvnewsjournal.com - February 21 at 3:42 PM
News IconAnalysts Weigh in on Achaogen, Inc. (NASDAQ:AKAO) - Rockville Register (NASDAQ:AKAO)
rockvilleregister.com - February 21 at 6:53 AM
News IconThe Charts For Achaogen, Inc. (AKAO) Is Speaking Volumes Today - NY Stock News (NASDAQ:AKAO)
nystocknews.com - February 18 at 3:25 PM
4-traders.com logoAchaogen : to Host R&D Day Focused on Advances and Opportunities in the Treatment of Resistant Gram-Negative Infections (NASDAQ:AKAO)
www.4-traders.com - February 16 at 7:37 AM
finance.yahoo.com logoAchaogen to Host R&D Day Focused on Advances and Opportunities in the Treatment of Resistant Gram-Negative Infections (NASDAQ:AKAO)
finance.yahoo.com - February 16 at 7:37 AM
News IconShares Losing Ground: Achaogen, Inc. (NASDAQ:AKAO) - Aiken Advocate (NASDAQ:AKAO)
aikenadvocate.com - February 13 at 8:54 PM
News IconA Look Ahead For 2 Stocks: Achaogen, Inc. (AKAO), Apollo Investment Corporation (AINV) - Post Analyst (NASDAQ:AKAO)
postanalyst.com - February 10 at 3:52 PM
News IconForward Earnings Estimate of Achaogen, Inc.(AKAO) - Highland Mirror (NASDAQ:AKAO)
www.highlandmirror.com - February 10 at 3:52 PM
finance.yahoo.com logoAchaogen to Participate in the Leerink Partners 6th Annual Global Healthcare Conference (NASDAQ:AKAO)
finance.yahoo.com - February 9 at 8:30 PM
News IconShare Levels in Review for Achaogen Inc (AKAO) - Benton Bulletin (NASDAQ:AKAO)
bentonbulletin.com - February 9 at 3:28 PM
News IconAchaogen, Inc. (AKAO) stock coverage started with “Buy” in note to investors by Stifel Nicolaus - The Ledger Gazette (NASDAQ:AKAO)
ledgergazette.com - February 9 at 3:28 PM
finance.yahoo.com logo5 Drug Stocks Poised to Beat Earnings Estimates in Q4 (NASDAQ:AKAO)
finance.yahoo.com - February 9 at 3:28 PM
News IconAchaogen, Inc. (AKAO) in-depth technical analysis | Post Analyst - Post Analyst (NASDAQ:AKAO)
postanalyst.com - February 8 at 3:37 PM
forbes.com logoFour Biotech Stocks Breaking Out (NASDAQ:AKAO)
www.forbes.com - February 8 at 3:37 PM
marketexclusive.com logoAnalyst Activity – Stifel Nicolaus Initiates Coverage On Achaogen (NASDAQ:AKAO) With a Buy (NASDAQ:AKAO)
marketexclusive.com - February 7 at 3:53 PM
us.rd.yahoo.com logoCoverage initiated on Achaogen by Stifel (NASDAQ:AKAO)
us.rd.yahoo.com - February 7 at 3:53 PM
marketexclusive.com logoInsider Trading Activity Achaogen, Inc. (NASDAQ:AKAO) – General Counsel Sold 521 shares of Stock - Market Exclusive (NASDAQ:AKAO)
marketexclusive.com - February 1 at 1:37 AM
marketexclusive.com logoInsider Trading Activity Achaogen, Inc. (NASDAQ:AKAO) – CFO Sold 955 shares of Stock - Market Exclusive (NASDAQ:AKAO)
marketexclusive.com - January 31 at 3:34 PM
fool.com logoGrowth Investing 2017: 3 Stocks to Put on Your Radar (NASDAQ:AKAO)
www.fool.com - January 31 at 3:34 PM
marketexclusive.com logoInsider Trading Activity Achaogen, Inc. (NASDAQ:AKAO) – CEO Sold 1,431 shares of Stock (NASDAQ:AKAO)
marketexclusive.com - January 31 at 1:39 AM
News IconADX in View on Shares of Achaogen Inc (AKAO) - Springdale Times (NASDAQ:AKAO)
springdaletimes.com - January 30 at 3:37 PM
News IconHigh Volatility Moving the Needle For Shares of Achaogen, Inc. (NASDAQ:AKAO) - Wall Street Beacon (NASDAQ:AKAO)
wsbeacon.com - January 30 at 3:37 PM
investopedia.com logoTop 4 Pharmaceutical Stocks for 2017 (NASDAQ:AKAO)
www.investopedia.com - January 30 at 3:37 PM
News IconChart Watch: Checking on Shares of Achaogen Inc (AKAO) - Sherwood Daily (NASDAQ:AKAO)
sherwooddaily.com - January 28 at 3:27 PM
News IconShares Hitting The Skids, Bounding Lower Mid-Day: Achaogen, Inc. (NASDAQ:AKAO) - Wall Street Beacon (NASDAQ:AKAO)
wsbeacon.com - January 28 at 1:35 AM
News IconHigh Volatility Creating Buzz Mid-Session For Achaogen, Inc. (NASDAQ:AKAO) - Wall Street Beacon (NASDAQ:AKAO)
wsbeacon.com - January 27 at 3:34 PM
News IconWhat is the Street Saying About Achaogen, Inc. (NASDAQ:AKAO)? - Aiken Advocate (NASDAQ:AKAO)
aikenadvocate.com - January 26 at 3:40 PM
News IconSpot-check on CCI and RSI for Achaogen Inc (AKAO) - Springdale Times (NASDAQ:AKAO)
springdaletimes.com - January 26 at 3:40 PM
News IconInvestor Radar: Taking a Closer Look at Achaogen, Inc. (NASDAQ:AKAO) - The Tribune (NASDAQ:AKAO)
lakecitytribune.com - January 25 at 3:31 PM
News IconAchaogen Inc. (AKAO) stock starts with "Positive" rating in note to investors by Guggenheim - BNB Daily (blog) (NASDAQ:AKAO)
www.baseball-news-blog.com - January 24 at 3:47 PM
News IconAchaogen Inc (AKAO) is Initiated by Guggenheim to “Buy” | Hignland ... - Highland Mirror (NASDAQ:AKAO)
www.highlandmirror.com - January 23 at 8:29 PM

Social

What is Achaogen's stock symbol?

Achaogen trades on the NASDAQ under the ticker symbol "AKAO."

Where is Achaogen's stock going? Where will Achaogen's stock price be in 2017?

8 equities research analysts have issued 1-year target prices for Achaogen's shares. Their predictions range from $10.00 to $30.00. On average, they anticipate Achaogen's share price to reach $22.71 in the next twelve months.

When will Achaogen announce their earnings?

Achaogen is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.

What are analysts saying about Achaogen stock?

Here are some recent quotes from research analysts about Achaogen stock:

  • Aegis analysts commented, "Yesterday after market close, Achaogen announced that it had achieved a key strategic milestone in the development of its in-vitro diagnostic (IVD) assay for plazomicin. The assay will be used to apply therapeutic drug monitoring (TDM) with the goal of optimizing plazomicin dosing in patients with infections due to multi-drug resistant enterobacteriaceae. The combination of TDM with plazomicin's broad therapeutic window should allow for more personalized dosing in patient populations with variable pharmacokinetics. Currently, the company plans to have the commercial assay approved and available at product launch for plazomicin. We view the milestone achievement as incrementally positive." (2/23/2017)
  • According to Zacks Investment Research, "Achaogen, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae. Achaogen, Inc. is headquartered in South San Francisco, California. " (2/13/2017)

  • Wedbush analysts commented, "With a favorable risk/benefit profile demonstrated in each both CARE and EPIC patient populations, we expect plazomicin will become the treatment of choice for CRE infections. We also believe AKAO represents an attractive takeout candidate, although this may depend on additional clarity on the market opportunity and plazomicin's label potential. We are increasing our PT to $23 based on raising our pricing expectations upwards." (1/31/2017)
  • Guggenheim analysts commented, "We are are initiating coverage of AKAO with a BUY rating and a $30PT. We believe the sales potential for Plazomicin and AKAO's early stage pipeline will reach sales levels not yet reflected in consensus expectations. Therefore, earnings upside and multiple expansion should drive AKAO shares higher, in our view. Our belief is supported by three points:#1 ' There is a strong likelihood that AKAO will receive approval for Plazomicin. This is because of the robust Phase 3 trial results from EPIC and CARE, and the increasing need for novel drugs to treat antibiotic-resistant bacteria.#2 ' We are optimistic about AKAO's early stage pipeline, which is a free call option on the stock, in our view. The pipeline includes small molecules and antibodies. AKAO expects to move one small molecule antibacterial into the clinic this year. AKAO will also host a R&D day in 1Q17, which should improve visibility for its early stage assets.#3 ' AKAO is an interesting company in a consolidating industry. Several antibiotic companies were acquired for $500M-$700MM. AKAO has a market cap of $613MM already, but we think AKAO has more differentiated drugs than the recently acquired companies. The largest deal was MRK's acquisition of Cubist in 2014 for $9.5B." (1/23/2017)
  • Cowen and Company analysts commented, "AKAO moved up Plazomicin (Plz) pivotal Ph3 EPIC cUTI top-line and CARE trial data." (11/28/2016)

Who owns Achaogen stock?

Achaogen's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (10.59%), Foresite Capital Management III LLC (9.50%), Renaissance Technologies LLC (1.37%), Bogle Investment Management L P DE (1.24%), Nicholas Investment Partners LP (0.58%) and Russell Investments Group Ltd. (0.39%). Company insiders that own Achaogen stock include Blake Wise, Equity Opportunities Iv Growth, Gary Loeb, Ian Friedland, Kenneth J Hillan, Tobin Schilke and Zeryn Sarpangal.

Who bought Achaogen stock? Who is buying Achaogen stock?

Achaogen's stock was acquired by a variety of institutional investors in the last quarter, including Foresite Capital Management III LLC, Bogle Investment Management L P DE, FMR LLC, Nicholas Investment Partners LP, Russell Investments Group Ltd., Renaissance Technologies LLC, Opaleye Management Inc. and Paulson & CO. Inc..

How do I buy Achaogen stock?

Shares of Achaogen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Achaogen stock cost?

One share of Achaogen stock can currently be purchased for approximately $23.65.

Achaogen (NASDAQ:AKAO) Chart for Friday, February, 24, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Achaogen (NASDAQ:AKAO)

Earnings History Chart

Earnings by Quarter for Achaogen (NASDAQ:AKAO)

Dividend History Chart

Dividend Payments by Quarter for Achaogen (NASDAQ:AKAO)

Last Updated on 2/24/2017 by MarketBeat.com Staff